NBTX · Nanobiotix S.A.
$40.38
-2.06% last session
End-of-day data · updated 2026-07-24
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-134.9
Dividend yield
—
Beta
0.56
Avg volume
0M
Employees
0K
2D change
-2.06%
5D change
4.66%
10D change
-5.02%
30D change
15.14%
60D change
-3.56%
MTD change
0.18%
YTD change
71.06%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NBTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-04
Latest call per bank · past 12 months
UBS
Neutral$30.00
-25.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-04 | Leerink Partners | Maintains | Outperform | $37.00 → $46.00 |
| 2026-05-01 | UBS | Maintains | Neutral | $3.50 → $30.00 |
| 2026-04-02 | Guggenheim | Maintains | Buy | $26.00 → $36.00 |
| 2026-02-06 | Guggenheim | Maintains | Buy | $8.00 → $26.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 53 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.5% above the 50-day MA ($39.37).
- Price vs 200-day MA: Trading 34.6% above the 200-day MA ($29.39).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.07) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($5.80) and high ($55.07).
NBTX Price Chart
Loading chart for NBTX…
Fundamentals
About Nanobiotix S.A.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$120B 4.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$68B -15.3% YTD
ARGX
argenx SE
$58B 10.0% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -32.4% YTD
ONC
BeOne Medicines Ltd.
$34B 7.6% YTD
RPRX
Royalty Pharma plc
$34B 54.2% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.